Acerta Pharma
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
121 Oyster Point Blvd Fl 4, South San Fr...Phone Number
(650) 591-2800Website
www.acerta-pharma.comRevenue
$38.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Acerta Pharma
Acerta Pharma, a member of the AstraZeneca Group, specializes in covalent binding technology to develop novel, highly selective therapies for cancer, particularly in the field of haematology. The company focuses on creating investigational agents that directly kill cancer cells or enhance the immune system's ability to eliminate cancer. With a commitment to addressing blood cancers with high unmet needs, Acerta Pharma aims to deliver first-in-class and best-in-class medicines. Their research and development efforts are supported by a state-of-the-art facility in the Netherlands, fostering collaborations with academic and commercial partners.Explore more
Acerta Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acerta Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Acerta Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Acerta Pharma had a recent Job posting/layoffs
Acerta Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Acerta Pharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Acerta Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Acerta Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at Acerta Pharma
Check out if Acerta Pharma is spiking on competitors!
Recommended Actions
Find VP level buyers at Acerta Pharma
Find more new buyers
Compare Similar Companies to Acerta Pharma
Compare insights from companies similar to Acerta Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Acerta Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Acerta Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Acerta Pharma.
Acerta Pharma Tech Stack
A closer look at the technologies used by Acerta Pharma
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Acerta Pharma News & Media
Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
-- Plan to evaluate Forty Seven’s CD47 antibody in combination with rituximab and Calquence (acalabrutinib) -- -- Novel combination aims to leverage the macrophage component of the innate immune system and a targeted kinase inhibitor -- MENLO PARK, Calif., May 10, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced a collaboration with Acerta Pharma, AstraZenNew Long-Term Data on CALQUENCE Presented at ASH 2018
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for CALQUENCE® (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma (MCL) and updated results of an ongoing clinical trial assessing acalabrutinib monotherapy in treatment-naïve patients with chronic lymphocytic leukemia (CLL) at the 60th American Society of Hematology (ASH) Annual Meeting & ExAstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca, together with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, CA, December 1-4. New data include presentations on CALQUENCE® (acalabrutinib) and LUMOXITI™ (moxetumomab pasudotox-tdfk), as well as rese
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acerta Pharma
Sign Up For FreeTo access detailed company insights
Acerta Pharma, a member of the AstraZeneca Group, specializes in covalent binding technology to develop novel, highly selective therapies for cancer, particularly in the field of haematology. The company focuses on creating investigational agents that directly kill cancer cells or enhance the immune system's ability to eliminate cancer. With a comm... Read More
